C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout
Financially stable C4 Therapeutics (CCCC) is worth watching for patient investors, but current lack of definitive data poses ...
Analysts Set C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target at $10.50
Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) have received an average rating of “Hold” from the five ...
C4 Therapeutics Advances in Protein Degradation Therapy
C4 Therapeutics, Inc. ( (CCCC) ) has released its Q3 earnings. Here is a breakdown of the information C4 Therapeutics, Inc. presented to its ...
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced its partner Betta Pharmaceuticals ...
C4 Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 12%. Looking ...
KTLA29d
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.
Oct. 15, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today ...
The Bakersfield Californian8d
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple ...
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that two abstracts ...
Yahoo Finance7d
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial
WATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation ...